Checkpoint Inhibitors Plus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

References

• BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• SiegelRL , MillerKD , JemalA. Cancer statistics, 2019. CA Cancer J. Clin.69(1), 7–34 (2019).
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975–2010. National Cancer Institute, MD, USA (2018). https://seer.cancer.gov/csr/1975_2014/
   Google Scholar
• RittmeyerA , BarlesiF , WaterkampDet al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase III, open-label, multicentre randomised controlled trial. Lancet389(10066), 255–265 (2017).
   PubMed Web of Science ®Google Scholar
• HerbstRS , BaasP , KimD-Wet al.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet387(10027), 1540–1550 (2016).
   PubMed Web of Science ®Google Scholar
• BorghaeiH , Paz-AresL , HornLet al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• BrahmerJ , ReckampKL , BaasPet al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• FülöpA , LubinieckiGM , TafreshiAet al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• SpilaA , RoselliM , GuadagniFet al.Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology2(10), e27025 (2013).
   PubMed Web of Science ®Google Scholar
• BracciL , SchiavoniG , SistiguA , BelardelliF. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ.21(1), 15–25 (2014).
   PubMed Web of Science ®Google Scholar
• LynchTJ , BondarenkoI , LuftAet al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol.30(17), 2046–2054 (2012).
   PubMed Web of Science ®Google Scholar
• GovindanR , SzczesnaA , AhnM-Jet al.Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J. Clin. Oncol.35(30), 3449–3457 (2017).
   PubMed Web of Science ®Google Scholar
• HigginsJPT , GreenS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration (2011). http://www.cochrane-handbook.org
   Google Scholar
• HigginsJPT AltmanDG. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series.HigginsJPT, GreenS (Eds). Wiley, NJ, USA, 187–241 (2008).
   Google Scholar
• HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG. Measuring inconsistency in meta-analyses. BMJ327(7414), 557–560 (2003).
   PubMed Web of Science ®Google Scholar
• LangerCJ , GadgeelSM , BorghaeiHet al.Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, Phase II cohort of the open-label KEYNOTE-021 study. Lancet Oncol.17(11), 1497–1508 (2016).
   PubMed Web of Science ®Google Scholar
• WestH , McCleodM , HusseinMet al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol.20(7), 924–937 (2019).
   PubMed Web of Science ®Google Scholar
• GandhiL , Rodríguez-AbreuD , GadgeelSet al.Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Paz-AresL , LuftA , VicenteDet al.Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• CappuzzoF , McCleodM , HusseinMet al.IMpower130: progression-free survival (PFS) and safety analysis from a randomised Phase III study of carboplatin+nab-paclitaxel (CnP) with or withoutatezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann. Oncol. 29(Suppl. 8), mdy424–065 (2018).
   Google Scholar
• JotteRM , CappuzzoF , VynnychenkoIet al.IMpower131: primary PFS and safety analysis of a randomized Phase III study of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J. Clin. Oncol.36(Suppl.18), LBA9000 (2018).
   Web of Science ®Google Scholar
• PapadimitrakopoulouV , CoboM , BordoniRet al.IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC. J. Thorac. Oncol.13(Suppl. 10), S332–S333 (2018).
   Web of Science ®Google Scholar
• SocinskiMA , JotteRM , CappuzzoFet al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med.378(24), 2288–2301 (2018).
   PubMed Web of Science ®Google Scholar
• SocinskiMA , JotteRM , CappuzzoFet al.Overall survival (OS) analysis of IMpower150, a randomized Phase III study of atezolizumab (atezo)+ chemotherapy (chemo) ± bevacizumab (bev) vs chemo+ bev in 1L nonsquamous (NSQ) NSCLC. J. Clin. Oncol.36(Suppl. 15), 9002 (2018).
   Web of Science ®Google Scholar
• BorghaeiH , HellmannMD , Paz-AresLGet al.Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227. J. Clin. Oncol.36(Suppl. 15), 9001 (2018).
   Web of Science ®Google Scholar
• ReckM , GeeseWJ , ChangHet al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med.378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• ChenR , HouX , YangL , ZhaoD. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis. Thorac. Cancer.10(4), 607–623 (2019).
   PubMed Web of Science ®Google Scholar
• XuX , HuangZ , ZhengL , FanY. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. Int. J. Cancer142(11), 2344–2354 (2018).
   PubMed Web of Science ®Google Scholar
• ShenK , CuiJ , WeiYet al.Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: a meta-analysis. J. Thorac. Dis.10(12), 6636–6652 (2018).
   PubMed Web of Science ®Google Scholar
• AddeoA , BannaGL , MetroG , DiMaio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front. Oncol.9, 264 (2019).
   PubMed Web of Science ®Google Scholar